Home > Healthcare > Pharmaceuticals > Finished Drug Form > Triptorelin Market
Triptorelin Market Size
Triptorelin Market size was valued at over USD 910 million in 2022. Driven by the growing occurrence of endometriosis across the global female population, industry is expected to grow at over 5% CAGR from 2023 to 2032.
Endometriosis is a disease that leads to scar tissue formation within the pelvis due to a chronic inflammatory response caused by the presence of endometrium outside the uterus. As per estimates, around 176 million women across the globe, around one in ten, suffer from endometriosis in their reproductive years, typically between the ages of 15 and 49. Triptorelin is efficacious in alleviating the pain symptoms caused by endometriosis. It has a favorable safety profile and has also been shown to improve reproductive function. Subsequently, it is commonly used to treat deep infiltrating endometriosis (DIE) among women.
| Report Attributes | Details |
|---|---|
| Base Year: | 2022 |
| Market Size in 2022: | USD 913 Million |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR: | 5% |
| 2032 Value Projection: | USD 1.49 Billion |
| Historical Data for: | 2018 to 2022 |
| No. of Pages: | 320 |
| Tables, Charts & Figures: | 373 |
| Segments covered: | Drug, Product form, Application, Route of Administration, Distribution Channel, and Region |
| Growth Drivers: | |
| Pitfalls & Challenges: |
Steep prices of triptorelin drugs may hamper industry outlook
Despite an extensive customer pool, triptorelin market faces a major challenge in the form of the high manufacturing cost of triptorelin drugs, which translates into steep medication prices for customers. Given that the raw materials utilized are specific to the drug, the quality of raw materials used in drug development is crucial, which further elevates costs. Meanwhile, the complexity of triptorelin manufacturing process, which entails a wide range of biological or chemical processes, is also impeding product adoption by limiting product availability to those who can afford it.
Triptorelin Market Analysis
Based on drug, triptorelin market share from triptorelin embonate segment is anticipated to grow at over 5% CAGR from 2023 to 2032, driven primarily by the growing number of prostate cancer cases worldwide. According to Global Cancer Observatory, GLOBOCAN, over 1.4 million prostate cancer cases were reported worldwide in 2020. Triptorelin embonate sees high demand owing to its efficacy in the treatment of advanced prostate cancer.
The intramuscular administration of 22.5 grams of triptorelin embonate in a 6-month formulation among men with advanced prostate cancer has been shown to initially increase their serum testosterone levels. It is also generally well-tolerated in such patients and has only mild severity of adverse reactions.
With respect to application, cancer segment accounted for more than 25% of the overall triptorelin industry share in 2022, on account of growing prevalence of cancer across the globe. As per WHO, cancer is the leading cause of death around the world and was responsible for nearly 10 million deaths in 2020. Prostate cancer, especially, is pegged to lead the charge by notably elevating the demand for triptorelin-based drugs. According to recent estimates from the American Cancer Society, the US is likely to record over 288,300 new cases of prostate cancer in 2023 alone.
Based on the route of administration, triptorelin market share from intradermal segment is likely to grow at over 4.5% CAGR from 2023 to 2032, fueled by the growing number of hormone therapies performed annually across the globe. Intradermal injections are widely utilized in such therapeutic procedures, which fosters the segment demand. They can also be used in TB tests, sensitivity tests for allergies, local anesthetic, and others. Intradermal delivery of vaccines is more efficient than injection into the subcutaneous tissue or muscle and reduces the antigen volume.
Europe triptorelin market is anticipated to reach a valuation of more than USD 370 million by 2032, owing to numerous industry players focusing on expanding their footprint across several European countries. Meanwhile, Europe is also increasingly investing on the health and well-being of its citizens to effectively address the increasing occurrence of endometriosis, cancer in the region. In fact, the region reports over 1.9 million deaths and 3.7 million new cases of cancer annually, making the disease its second leading cause of death and morbidity. In addition, rising disposable income has proliferated the demand for triptorelin-based drugs by bringing them in reach of more customers.
Triptorelin Market Share
Some prominent triptorelin market players include
- Varian Pharmed
- Verity Pharmaceuticals Inc.
- LGM Pharma.
- Ipsen Pharma
- BACHEM
- Ferring B.V.
- Merck & Co., Inc.
- Taj Pharmaceuticals Limited
- Dr. Reddy’s Laboratories Ltd.
Many of these companies are emphasizing partnership and collaborations to expand their industry influence. Citing an instance, Amneal Pharmaceuticals, an American pharma company, announced a long-term partnership agreement with Orion Corporation, a Finnish pharma company in January 2023, to commercialize many of Amneal’s complex generic products.
Through this agreement, the company’s complex generic programs will be displayed by Orion in New Zealand, Australia, and most parts of Europe. It will help the company reinforce its product portfolio in Europe.
Impact of the COVID-19 pandemic
COVID-19 pandemic resulted in changes in buying and stocking patterns, R&D processes, regulations, and demand, and supply shortages. The stockpiling of pharmaceutical products by stakeholders declined sales in the initial few months of 2020. It negatively affected the pharmaceutical and healthcare sector. The short-term implications of the pandemic on the industry were mixed. However, the market is set to flourish due to growing demand for few pharmaceutical products and rising acceptance of active pharma ingredients including triptorelin in drug development.
The triptorelin market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue in USD from 2018 to 2032 for the following segments: Click here to Buy Section of this Report
By Drug
- Triptorelin Pamoate
- Triptorelin Acetate
- Triptorelin Embonate
By Product Form
- Pre-filled Syringes
- Vials
- Lyophilized Powder
By Application
- Cancer
- Endometriosis
- Uterine Fibroids
- Central Precocious Puberty
- Hormone Therapy
- Radical Prostatectomy
- Others
- Total
By Route of Administration
- Intramuscular
- Subcutaneous
- Intradermal
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
The above information is provided for the following regions and countries:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Others
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Philippines
- CIS
- Thailand
- Vietnam
- Others
- Latin America
- Brazil
- Mexico
- Argentina
- Chile
- Colombia
- Peru
- Guatemala
- Costa Rica
- Others
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Yemen
- Iraq
- Lebanon
- Syria
- Others
Frequently Asked Questions (FAQ) :